DBV Technologies S.A. (NASDAQ:DBVT) was downgraded by equities researchers at Societe Generale from a “buy” rating to a “sell” rating in a report released on Tuesday, The Fly reports.

A number of other research firms have also recently weighed in on DBVT. BidaskClub cut shares of DBV Technologies from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Morgan Stanley reaffirmed an “overweight” rating and set a $72.00 target price (up previously from $70.00) on shares of DBV Technologies in a research note on Friday, October 6th. Leerink Swann set a $49.00 target price on shares of DBV Technologies and gave the stock an “outperform” rating in a research note on Monday. Zacks Investment Research cut shares of DBV Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, August 31st. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a research note on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. DBV Technologies currently has an average rating of “Buy” and a consensus target price of $51.63.

DBV Technologies (DBVT) opened at 28.32 on Tuesday. DBV Technologies has a 12-month low of $22.33 and a 12-month high of $50.57. The firm’s 50-day moving average price is $44.48 and its 200 day moving average price is $39.50. The firm’s market cap is $1.30 billion.

ILLEGAL ACTIVITY WARNING: “DBV Technologies S.A. (DBVT) Downgraded by Societe Generale” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/24/dbv-technologies-s-a-dbvt-downgraded-by-societe-generale.html.

Several institutional investors have recently modified their holdings of DBVT. Dynamic Technology Lab Private Ltd bought a new stake in shares of DBV Technologies in the second quarter worth $222,000. Victory Capital Management Inc. bought a new stake in shares of DBV Technologies in the first quarter worth $303,000. Airain ltd bought a new stake in shares of DBV Technologies in the second quarter worth $333,000. Sit Investment Associates Inc. bought a new stake in shares of DBV Technologies in the second quarter worth $698,000. Finally, Jane Street Group LLC bought a new stake in shares of DBV Technologies in the first quarter worth $853,000. 45.52% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

The Fly

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.